2019•Journal of Cosmetic DermatologyRequires access

Serum interleukin‐17 as a novel biomarker in patients with acne vulgaris

Adel Ali Ebrahim, Amany Ibrahim Mustafa, Awad M. Elabd

Open publisher page 19 citations

Abstract

BACKGROUND: Acne vulgaris is a common chronic inflammatory skin disease involving pilosebaceous units. Both innate and adaptive immunity, especially the T helper 17 pathway, may contribute to the inflammatory response in acne. OBJECTIVES: We aimed at evaluation of serum interleukin-17 (IL-17) level in patients with acne vulgaris in order to assess its role in disease pathogenesis and its clinical significance. METHODS: Serum IL-17 level was measured by an ELISA technique in 80 acne vulgaris patients and 80 apparently healthy controls. RESULTS: Serum IL-17 level was significantly higher in acne vulgaris patients than control group (P < 0.001). Moreover, it was increasing significantly with the increase in disease severity and in patients with scarring lesions (P < 0.001 each). CONCLUSIONS: Serum IL-17 is not only a biomarker of disease pathogenesis but also it could be a potential prognostic predictor for severity and scarring in acne vulgaris.

About this research paper

What this paper is about

BACKGROUND: Acne vulgaris is a common chronic inflammatory skin disease involving pilosebaceous units. Both innate and adaptive immunity, especially the T helper 17 pathway, may contribute to the inflammatory response in acne. OBJECTIVES: We aimed at evaluation of serum interleukin-17 (IL-17) level in patients with acne vulgaris in order to assess its role in disease pathogenesis and its clinical significance. METHODS: Serum IL-17 level was measured by an ELISA technique in 80 acne vulgaris patients and 80 apparently healthy controls. RESULTS: Serum IL-17 level was significantly higher in acne vulgaris patients than control group (P < 0.001). Moreover, it was increasing significantly with the increase in disease severity and in patients with scarring lesions (P < 0.001 each). CONCLUSIONS: Serum IL-17 is not only a biomarker of disease pathogenesis but also it could be a potential prognostic predictor for severity and scarring in acne vulgaris.

Why it matters

OpenAlex reports 19 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

BACKGROUND: Acne vulgaris is a common chronic inflammatory skin disease involving pilosebaceous units. Both innate and adaptive immunity, especially the T helper 17 pathway, may contribute to the inflammatory response in acne. OBJECTIVES: We aimed at evaluation of serum interleukin-17 (IL-17) level in patients with acne vulgaris in order to assess its role in disease pathogenesis and its clinical significance. METHODS: Serum IL-17 level was measured by an ELISA technique in 80 acne vulgaris patients and 80 apparently healthy controls. RESULTS: Serum IL-17 level was significantly higher in acne vulgaris patients than control group (P < 0.001). Moreover, it was increasing significantly with the increase in disease severity and in patients with scarring lesions (P < 0.001 each). CONCLUSIONS: Serum IL-17 is not only a biomarker of disease pathogenesis but also it could be a potential prognostic predictor for severity and scarring in acne vulgaris.

Key concepts: Acne, Medicine, Pathogenesis, Biomarker, Disease, Interleukin, Immunology, Gastroenterology

Related papers

Back to paper searchBrowse research topicsOriginal source
Serum interleukin‐17 as a novel biomarker in patients with acne vulgaris — Research Paper | ScholarLens